Start here if you're new
what it is
EyePoint makes eye-disease medicines and slow-release eye implants.
how it gets paid
Last year Eyepoint made $31M in revenue. DEXYCU sales was the main engine at $12M, or 39% of sales.
why growth slowed
Revenue fell 27.5% last year. Revenue was $31M, but EPS was still -$2.35, so the company is growing sales without earning profit yet.
what just happened
Revenue hit $31M, while EPS stayed at -$2.35.
At a glance
B balance sheet — gets the job done, barely
55/100 earnings predictability — expect surprises
-$2.32 fy2024 eps est
$42M fy2024 rev est
n/a operating margin
xvary composite: 48/100 — below average
What they do
EyePoint makes eye-disease medicines and slow-release eye implants.
Its Durasert E platform is a drug depot, which means medicine sits in the eye and releases slowly. That matters because you want fewer shots, not more. EyePoint has 165 employees, so your money is riding on a small team with a big pipeline.
How they make money
$31M
annual revenue · their business grew -27.5% last year
DEXYCU sales
$12M
YUTIQ sales
$10M
Licensing and royalties
$5M
Other revenue
$4M
The products that matter
lead wet AMD candidate
Duravyu
2026 pivotal data · no approved revenue
It has no approved revenue today, but pivotal data expected in 2026 is doing most of the work behind the company's roughly $1B valuation.
clinical catalyst
commercial eye implant
YUTIQ
$31M product revenue · 94% gross margin
It proves the delivery platform can generate real sales, but revenue fell 27.5%, so it is validation, not the main growth engine.
proof of platform
Key numbers
-$2.32
fy2024 eps est
$42M
fy2024 rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $21M (2% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for EYPT right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $31M, while EPS stayed at -$2.35.
The business is still spending more than it makes. A 3083% revenue jump sounds huge, but losses are still in the picture.
$31M
revenue
$2.35
eps
+3083%
revenue vs. last year
the number that mattered
Revenue was $31M, but EPS was still -$2.35, so the company is growing sales without earning profit yet.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Duravyu failing to validate the platform in 2026.
med
binary clinical failure
The company's roughly $1B valuation hinges on pivotal Duravyu data expected in 2026. There is no approved Duravyu revenue to cushion a miss.
If the data disappoints, investors are left with a $31M product base that is already shrinking.
med
cash burn and dilution
Operating margin n/a (verify filings), and the latest quarter still showed a $0.81 per-share loss on just $5.3M of revenue.
That gap usually gets funded with new capital. For you, that means more dilution risk before the science settles the story.
med
commercial revenue keeps sliding
Product revenue fell 27.5%, even with a 94% gross margin. High margin does not help much when the revenue line is moving the wrong way.
If YUTIQ keeps shrinking, the company becomes even more dependent on one pipeline readout.
med
headline volatility before data
A 1.6 beta, 5 / 100 price stability score, and sector disputes over safety framing create a stock that can move hard on partial information.
You can be directionally right on the science and still sit through violent moves before the actual readout arrives.
A failed Duravyu readout would leave a $1B company supported by just $31M of product revenue, a 27.5% product-sales decline, and a n/a operating margin.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
Duravyu pivotal data readout
Top-line results from the pivotal diabetic macular edema program are expected in 2026. That's the event the whole stock trades around.
commercial
whether product revenue stabilizes
The current base is $31M and it fell 27.5%. If the commercial side keeps shrinking, pipeline dependence gets even higher.
financing
any new capital raise
A n/a operating margin tells you the present business does not self-fund the pipeline. Funding headlines matter here.
street view
how the $20–$68 target range shifts
When analysts are that spread out, target changes often tell you more about sentiment into data than about the current income statement.
Analyst rankings
earnings predictability
55 / 100
in human-speak, analysts do not have a clean model here because the stock trades on clinical milestones more than steady fundamentals.
price stability
5 / 100
This is the opposite of a low-drama stock. You should expect sharp moves around trial, funding, and sector headlines.
balance sheet grade
B
Adequate balance sheet grade for now. Not bad enough to break the thesis by itself, not strong enough to ignore dilution risk.
source: institutional data
Institutional activity
institutional ownership data for EYPT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$16
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive